Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery – preliminary 6 month results

Clinical and Experimental Ophthalmology

Volumn 44, Issue 4, 2016, Pages 233-242

  Lim, Lyndell L ^a,b   Morrison, Julie L ^a   Constantinou, Marios ^a   Rogers, Sophie ^a   Sandhu, Sukhpal S ^a,b   Wickremasinghe, Sanjeewa S ^a,b   Kawasaki, Ryo ^c   Al Qureshi, Salmaan ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

bevacizumab; cataract surgery; diabetic macular oedema; randomized clinical trial; triamcinolone

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; AUSTRALIA; CATARACT; CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY;

EID: 84974808096     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12720     Document Type: Article

References (45)

1. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA: the journal of the American Medical Association 2007; 298: 902–16.
2. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol 2008; 126: 1740–7.
3. Wong T, Klein K. The epidemiology of eye diseases in diabetes. In: Ekoé J, Rewers M, Williams R, Zimmet P, eds. The Epidemiology of Diabetes Mellitus (2nd ed). Oxford: John Wiley and Sons, 2008; 475–97.
4. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48–58.
5. Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies. Am J Ophthalmol 1981; 91: 381–95.
6. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Am J Ophthalmol 1995; 119: 295–300.
7. Jaffe GJ, Burton TC, Kuhn E, Prescott A, Hartz A. Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. Am J Ophthalmol 1992; 114: 448–56.
8. Baker CW, Almukhtar T, Bressler NM et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmology 2013; 131: 870–9.
9. Bressler SB, Baker CW, Almukhtar T et al. Pilot study of individuals with diabetic macular edema undergoing cataract surgery. JAMA Ophthalmology 2013: p. -.
10. Dowler JG, Sehmi KS, Hykin PG, Hamilton AM. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999; 106: 663–8.
11. Dowler J, Hykin PG. Cataract surgery in diabetes. Curr Opin Ophthalmol 2001; 12: 175–8.
12. Somaiya M, Burns JD, Mintz R, Warren RE, Uchida T, Godley BF. Factors affecting visual outcomes after small-incision phacoemulsification in diabetic patients. J Cataract Refract Surg 2002; 28: 1364–71.
13. Eriksson U, Alm A, Bjärnhall G, Granstam E, Matsson A. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. Graefes Arch Clin Exp Ophthalmol 2011; 249: 349–59.
14. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–25.
15. Nguyen QD, Brown DM, Marcus DM et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789–801.
16. Moradi A, Sepah YJ, Sadiq MA et al. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4: 303–9.
17. Wells JA, Glassman AR, Ayala AR et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193–203.
18. Rajendram R, Fraser-Bell S, Kaines A et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972–9.
19. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina 2009; 29: 530–5.
20. Chae JBMD, Joe SGMD, Yang SJMD et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina 2014; 34: 149–56.
21. Chen CH, Liu YC, Wu PC. The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema. J Ocul Pharmacol Ther 2009; 25: 83–9.
22. Bresnick GH. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 1983; 90: 1301–17.
23. Miyake K, Mibu H, Horiguchi M, Shirasawa E. Inflammatory mediators in postoperative aphakic and pseudophakic baboon eyes. Arch Ophthalmol 1990; 108: 1764–7.
24. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001; 411: 231–43.
25. Gillies MC, Islam FM, Zhu M, Larsson J, Wong TY. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007; 91: 1323–6.
26. Nguyen QD, Shah SM, Heier JS et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116: 2175–81 e2171.
27. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115 1447-9, 1449 e1441-1410.
28. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92: 76–80.
29. The Royal Australian and New Zealand College of Ophthalmologists. Guidelines for Performing Intravitreal Injections, 2006.
30. Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Stat Med 2000; 19: 861–77.
31. Pollack A, Leiba H, Bukelman A, Oliver M. Cystoid macular oedema following cataract extraction in patients with diabetes. Br J Ophthalmol 1992; 76: 221–4.
32. Hayashi K, Igarashi C, Hirata A, Hayashi H. Changes in diabetic macular oedema after phacoemulsification surgery. Eye 2007; 23: 389–96.
33. Zaczek A, Olivestedt G, Zetterstrom C. Visual outcome after phacoemulsification and IOL implantation in diabetic patients. Br J Ophthalmol 1999; 83: 1036–41.
34. Elman MJ, Aiello LP, Beck RW et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064–77 e1035.
35. Fard MA, Yazdanei Abyane A, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study. Eur J Ophthalmol 2011; 21: 276–81.
36. Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009; 116: 1151–7.
37. Rauen PIMD, Ribeiro JASMD, Almeida FPPMD, Scott IUMDMPH, Messias AMDP, Jorge RMDP. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina 2012; 32: 1799–803.
38. Ahmadabadi HF, Mohammadi M, Beheshtnejad H, Mirshahi A. Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification. J Cataract Refract Surg 2010; 36: 917–22.
39. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood–retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155–9.
40. Lam DS, Chan CK, Mohamed S et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye (Lond) 2005; 19: 885–90.
41. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008; 31: 1541–6.
42. Callanan DG, Gupta S, Boyer DS et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843–51.
43. Kim SY, Yang J, Lee YC, Park YH. Effect of a single intraoperative sub-Tenon injection of triamcinolone acetonide on the progression of diabetic retinopathy and visual outcomes after cataract surgery. J Cataract Refract Surg 2008; 34: 823–6.
44. Takata C, Messias A, Folgosa MS et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. Retina 2010; 30: 562–9.
45. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005; 24: 587–611.